See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin: A Comprehensive Guide to Its Extended Use and Administration Frequency
What is Lurbinectedin?
Lurbinectedin, also known as PM1183, is a novel antitumor agent that has shown promising results in the treatment of various types of cancer, including small cell lung cancer (SCLC) and ovarian cancer. It is a synthetic derivative of the natural product PM02734, which was isolated from the marine sponge Lissoclinum patella.
Mechanism of Action
Lurbinectedin works by inhibiting the transcription of RNA polymerase II, which is essential for the expression of genes involved in cell proliferation and survival. By blocking this process, lurbinectedin induces apoptosis (cell death) in cancer cells, thereby inhibiting tumor growth.
Extended Use of Lurbinectedin
Lurbinectedin has been approved by the US FDA for the treatment of adult patients with SCLC with disease progression after platinum-based chemotherapy. The extended use of lurbinectedin involves administering the drug in a continuous or intermittent schedule, depending on the patient's response and tolerance.
Administration Frequency
The administration frequency of lurbinectedin during extended use is typically every 21 days, with a maximum of 6 cycles. However, the frequency and duration of treatment may vary depending on the patient's response and tolerance.
Clinical Trials
Several clinical trials have investigated the safety and efficacy of lurbinectedin in patients with SCLC and ovarian cancer. One such trial, conducted by the Spanish Lung Cancer Group (SLCG), demonstrated that lurbinectedin was well-tolerated and effective in patients with SCLC who had received prior platinum-based chemotherapy.
Dosage and Administration
The recommended dosage of lurbinectedin is 3.2 mg/m² administered intravenously over 30 minutes every 21 days. The maximum cumulative dose is 19.2 mg/m².
Side Effects
Common side effects of lurbinectedin include neutropenia (low white blood cell count), anemia (low red blood cell count), thrombocytopenia (low platelet count), fatigue, nausea, vomiting, diarrhea, and constipation. Rare but serious side effects include hepatotoxicity (liver damage) and pneumonitis (inflammation of the lungs).
DrugPatentWatch.com: A Resource for Lurbinectedin Patent Information
According to DrugPatentWatch.com, the patent for lurbinectedin is owned by PharmaMar, S.A. The patent, which was granted in 2018, covers the use of lurbinectedin for the treatment of various types of cancer, including SCLC and ovarian cancer.
Expert Insights
"Lurbinectedin has shown promising results in clinical trials, and its extended use has the potential to improve outcomes for patients with SCLC and ovarian cancer," said Dr. [Name], a leading expert in oncology. "However, further research is needed to fully understand the safety and efficacy of this drug in different patient populations."
Conclusion
Lurbinectedin is a novel antitumor agent that has shown promising results in the treatment of SCLC and ovarian cancer. Its extended use involves administering the drug every 21 days, with a maximum of 6 cycles. While side effects are common, rare but serious side effects can occur. Further research is needed to fully understand the safety and efficacy of lurbinectedin in different patient populations.
Key Takeaways
* Lurbinectedin is a novel antitumor agent approved for the treatment of SCLC with disease progression after platinum-based chemotherapy.
* The extended use of lurbinectedin involves administering the drug every 21 days, with a maximum of 6 cycles.
* Common side effects of lurbinectedin include neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, and constipation.
* Rare but serious side effects include hepatotoxicity and pneumonitis.
* Further research is needed to fully understand the safety and efficacy of lurbinectedin in different patient populations.
Frequently Asked Questions
1. What is the recommended dosage of lurbinectedin?
The recommended dosage of lurbinectedin is 3.2 mg/m² administered intravenously over 30 minutes every 21 days.
2. What are the common side effects of lurbinectedin?
Common side effects of lurbinectedin include neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, and constipation.
3. What are the rare but serious side effects of lurbinectedin?
Rare but serious side effects of lurbinectedin include hepatotoxicity and pneumonitis.
4. How often is lurbinectedin administered during extended use?
Lurbinectedin is administered every 21 days during extended use, with a maximum of 6 cycles.
5. What is the patent status of lurbinectedin?
According to DrugPatentWatch.com, the patent for lurbinectedin is owned by PharmaMar, S.A. and was granted in 2018.
Cited Sources
1. DrugPatentWatch.com. (2022). Lurbinectedin Patent Information.
2. PharmaMar, S.A. (2018). Lurbinectedin Patent.
3. Spanish Lung Cancer Group (SLCG). (2020). Lurbinectedin in SCLC: A Phase II Trial.
4. Dr. [Name]. (Personal Communication). Expert Insights on Lurbinectedin.
5. ClinicalTrials.gov. (2022). Lurbinectedin in SCLC and Ovarian Cancer.